OBSIDIAN THERAPEUTICS INC
OBXNASDAQ🏆 #4905 by market capUS Equity
$14.57▲ $1.29 (+8.86%)
After hours · at closeTrack OBX
Get earnings, price moves & breaking news on Telegram
24h▲ 8.9%
7d▼ 14.3%
14d▼ 15.4%
30d▼ 11.8%
ytd—
1y—
🏦Market Cap
$15M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
52
Weak
Trading Snapshot
- Day Range
- $14.51 – $14.67
- 52-Week Range
- $12.16 – $49.97
- Volume
- $3.31B
- Avg Volume
- $2.51B
- Shares Outstanding
- 1.0M
- Next Earnings
- Oct 30, 2026
Fundamentals Snapshot
- Annual Revenue
- $2M
- Last Q Revenue
- $623,333
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- —
- Dividend Yield
- —
Why Investors Own OBX
- ✓High-growth profile — revenue up -1.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 69% gross margin and 20% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
OBSIDIAN THERAPEUTICS INC
OBXFinancial Trends
Revenue (TTM)The total money the company brought in from sales, before subtracting any costs.
$2M▼ −1.7% YoY
Gross Margin (TTM)Of every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
68.9%▲ +4.3% YoY
Operating Income (TTM)Profit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$667,023▼ −1.7% YoY
Free Cash Flow (TTM)Cash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$449,958▼ −1.7% YoY
StockOtter · stockotter.spaceAbout OBSIDIAN THERAPEUTICS INC
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
52/100
Analyst Price Target
ⓘAverage Target
$15.12
▲ +3.8% Upside
High Target$18.43
Low Target$13.78
Based on 18 analysts
Latest News & Updates
🚀
Barron’s·2h ago
OBSIDIAN THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift OBX price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
OBSIDIAN THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.